205 related articles for article (PubMed ID: 37651540)
1. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy.
Wellhausen N; O'Connell RP; Lesch S; Engel NW; Rennels AK; Gonzales D; Herbst F; Young RM; Garcia KC; Weiner D; June CH; Gill SI
Sci Transl Med; 2023 Sep; 15(714):eadi1145. PubMed ID: 37651540
[TBL] [Abstract][Full Text] [Related]
2. Epitope editing enables targeted immunotherapy of acute myeloid leukaemia.
Casirati G; Cosentino A; Mucci A; Salah Mahmoud M; Ugarte Zabala I; Zeng J; Ficarro SB; Klatt D; Brendel C; Rambaldi A; Ritz J; Marto JA; Pellin D; Bauer DE; Armstrong SA; Genovese P
Nature; 2023 Sep; 621(7978):404-414. PubMed ID: 37648862
[TBL] [Abstract][Full Text] [Related]
3. CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture.
Harfmann M; Schröder T; Głów D; Jung M; Uhde A; Kröger N; Horn S; Riecken K; Fehse B; Ayuk FA
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254824
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
Cooper ML; DiPersio JF
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968
[TBL] [Abstract][Full Text] [Related]
6. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.
Polgárová K; Otáhal P; Šálek C; Pytlík R
Front Oncol; 2022; 12():876758. PubMed ID: 35600381
[TBL] [Abstract][Full Text] [Related]
8. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
[TBL] [Abstract][Full Text] [Related]
9. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
10. Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells.
Fang KK; Lee J; Khatri I; Na Y; Zhang L
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678917
[TBL] [Abstract][Full Text] [Related]
11. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
Hu KJ; Yin ETS; Hu YX; Huang H
Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
[TBL] [Abstract][Full Text] [Related]
12. Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy.
Marone R; Landmann E; Devaux A; Lepore R; Seyres D; Zuin J; Burgold T; Engdahl C; Capoferri G; Dell'Aglio A; Larrue C; Simonetta F; Rositzka J; Rhiel M; Andrieux G; Gallagher DN; Schröder MS; Wiederkehr A; Sinopoli A; Do Sacramento V; Haydn A; Garcia-Prat L; Divsalar C; Camus A; Xu L; Bordoli L; Schwede T; Porteus M; Tamburini J; Corn JE; Cathomen T; Cornu TI; Urlinger S; Jeker LT
J Exp Med; 2023 Dec; 220(12):. PubMed ID: 37773046
[TBL] [Abstract][Full Text] [Related]
13. Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope.
Velasco-Hernandez T; Zanetti SR; Roca-Ho H; Gutierrez-Aguera F; Petazzi P; Sánchez-Martínez D; Molina O; Baroni ML; Fuster JL; Ballerini P; Bueno C; Fernandez-Fuentes N; Engel P; Menendez P
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788237
[TBL] [Abstract][Full Text] [Related]
14. Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances.
Liu J; Zhang Y; Guo R; Zhao Y; Sun R; Guo S; Lu W; Zhao M
Front Immunol; 2023; 14():1170968. PubMed ID: 37215124
[TBL] [Abstract][Full Text] [Related]
15. Efficient chimeric antigen receptor targeting of a central epitope of CD22.
Casey NP; Klee CH; Fåne A; Caulier B; Graczyk-Jarzynka A; Krawczyk M; Fidyt K; Josefsson SE; Köksal H; Dillard P; Patkowska E; Firczuk M; Smeland EB; Winiarska M; Myklebust JH; Inderberg EM; Wälchli S
J Biol Chem; 2023 Jul; 299(7):104883. PubMed ID: 37269947
[TBL] [Abstract][Full Text] [Related]
16. Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies.
Maganti HB; Kirkham AM; Bailey AJM; Shorr R; Kekre N; Pineault N; Allan DS
Cytotherapy; 2022 Apr; 24(4):405-412. PubMed ID: 35039239
[TBL] [Abstract][Full Text] [Related]
17. Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31658644
[TBL] [Abstract][Full Text] [Related]
18. Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.
Jiménez-Reinoso A; Tirado N; Martinez-Moreno A; Díaz VM; García-Peydró M; Hangiu O; Díez-Alonso L; Albitre Á; Penela P; Toribio ML; Menéndez P; Álvarez-Vallina L; Sánchez Martínez D
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564128
[TBL] [Abstract][Full Text] [Related]
19. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
Dai Z; Mu W; Zhao Y; Cheng J; Lin H; Ouyang K; Jia X; Liu J; Wei Q; Wang M; Liu C; Tan T; Zhou J
Signal Transduct Target Ther; 2022 Mar; 7(1):85. PubMed ID: 35332132
[TBL] [Abstract][Full Text] [Related]
20. Progress on CAR-T cell therapy for hematological malignancies.
Hu K; Huang Y; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):192-203. PubMed ID: 36161291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]